Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Global Anti-Fibrinolytic Drugs Market: By Form: Oral, Injectable; By Type: Amicor, Aminocaproic acid, Aprotinin, Lysteda, RiaSTAP, Fibrinogen, Tranexamic Acid, Trasylol, Others; By Indication; By End Use; Regional Analysis; Historical Market and Forecast (2016-2026); Competitive Landscape; Industry Events and Developments
Global Anti-Fibrinolytic Drugs Market Outlook
The global anti-fibrinolytic drugs market witnessed a healthy growth in the historical period of 2016-2020 aided by the rising healthcare sector in the emerging regions. The market is further expected to grow at a CAGR of 5% in the forecast period of 2021-2026.
North America to be a Significant Anti-Fibrinolytic Drugs Market
North America has been a significant market for anti-fibrinolytic drugs in the past years and is expected to continue the trend. This dominance of the region can be attributed to the rising numbers of severe road accidents and trauma. A significant proportion of the deaths in North America are reported to be caused by trauma. The rising incidences of platelet dysfunctions, Von Willebrand disease, haemophilia A and B, which require anti-fibrinolytic drugs to inhibit fibrinolysis, are expected to contribute to the growth of the anti-fibrinolytic drugs industry in North America. Europe, the Asia Pacific, and Latin America are the other significant markets for the drugs, apart from North America. The growing investments in healthcare R&D are expected to augment the anti-fibrinolytic drugs industry growth globally in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Anti-Fibrinolytic Drugs: Industry Definition and Segmentation
Fibrinolysis is a natural physiological process that prevents blood clotting. It is carried out by converting plasminogen to plasmin. It can cause persistent bleeding and trauma, which might ultimately lead to death. Anti-fibrinolytic drugs like aminocaproic acid and tranexamic acid are lysine-like agents that prevent plasmin (fibrinolytic enzyme) formation by hindering the binding sites of the enzyme at lysin-rich areas, thus, inhibiting fibrinolysis. These drugs are used in the treatment of various coagulation disorders and medical surgeries.
By form, the market can be segmented into:
- Oral
- Injectable
Based on type, the market can be classified into amicor, aminocaproic acid, aprotinin, lysteda, riaSTAP, fibrinogen, tranexamic acid, and trasylol, among others.
Based on indication, the market is segmented into:
- Gynaecology
- Hereditary Angioedema
- Fibrinolytic Response Testing
- Surgeries
- Others
Based on end-use, the market can be categorised into:
- Hospitals
- Ambulatory Surgery Centres
- Health Care Speciality Processes
- Clinics
The EMR report looks into the regional markets of North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
Rise in Road Accidents to Drive the Anti-Fibrinolytic Drugs Market Growth
The market is being driven by a significant rise in road accidents, which cause severe bleeding. Trauma is observed to be one of the significant mortality causes across the world, hence, increasing the demand for anti-fibrinolytic drugs. Further, the usage of the drugs in oral bleeding treatments is bolstering the market growth further. The rising adoption of these drugs for the treatment of menorrhagia, i.e., heavy menstrual flow, is expected to bolster the anti-fibrinolytic drugs industry in the coming years. The increasing investments in the R&D of hemophilia products are also predicted to influence the demand for the drugs in the forecast period.
Key Industry Players in the Global Anti-Fibrinolytic Drugs Market
The report presents a detailed analysis of the following key players in the global anti-fibrinolytic drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Pfizer Inc.
- Sanofi SA
- Akorn, Inc
- Cadila Healthcare Ltd.
- Takeda Pharmaceutical Company Limited
- Others
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2016-2020 |
| Forecast Period | 2021-2026 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Form, Type, Indication, End Use, Region |
| Breakup by Form | Oral, Injectable |
| Breakup by Type | Amicor, Aminocaproic acid, Aprotinin, Lysteda, RiaSTAP, Fibrinogen, Tranexamic Acid, Trasylol, Others |
| Breakup by Indication | Gynaecology, Hereditary Angioedema, Fibrinolytic Response Testing, Surgeries, Others |
| Breakup by End Use | Hospitals, Ambulatory Surgery Centres, Health Care Specialty Processes, Clinics |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Pfizer Inc., Sanofi SA, Akorn, Inc., Cadila Healthcare Ltd., Takeda Pharmaceutical Company Limited, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Anti-Fibrinolytic Drugs Market Analysis
8.1 Key Industry Highlights
8.2 Global Anti-Fibrinolytic Drugs Historical Market (2016-2020)
8.3 Global Anti-Fibrinolytic Drugs Market Forecast (2021-2026)
8.4 Global Anti-Fibrinolytic Drugs Market by Form
8.4.1 Oral
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2016-2020)
8.4.1.3 Forecast Trend (2021-2026)
8.4.2 Injectable
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2016-2020)
8.4.2.3 Forecast Trend (2021-2026)
8.5 Global Anti-Fibrinolytic Drugs Market by Type
8.5.1 Amicor
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2016-2020)
8.5.1.3 Forecast Trend (2021-2026)
8.5.2 Aminocaproic acid
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2016-2020)
8.5.2.3 Forecast Trend (2021-2026)
8.5.3 Aprotinin
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2016-2020)
8.5.3.3 Forecast Trend (2021-2026)
8.5.4 Lysteda
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2016-2020)
8.5.4.3 Forecast Trend (2021-2026)
8.5.5 RiaSTAP
8.5.5.1 Market Share
8.5.5.2 Historical Trend (2016-2020)
8.5.5.3 Forecast Trend (2021-2026)
8.5.6 Fibrinogen
8.5.6.1 Market Share
8.5.6.2 Historical Trend (2016-2020)
8.5.6.3 Forecast Trend (2021-2026)
8.5.7 Tranexamic Acid
8.5.7.1 Market Share
8.5.7.2 Historical Trend (2016-2020)
8.5.7.3 Forecast Trend (2021-2026)
8.5.8 Trasylol
8.5.8.1 Market Share
8.5.8.2 Historical Trend (2016-2020)
8.5.8.3 Forecast Trend (2021-2026)
8.5.9 Others
8.6 Global Anti-Fibrinolytic Drugs Market by Indication
8.6.1 Gynaecology
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2016-2020)
8.6.1.3 Forecast Trend (2021-2026)
8.6.2 Hereditary Angioedema
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2016-2020)
8.6.2.3 Forecast Trend (2021-2026)
8.6.3 Fibrinolytic Response Testing
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2016-2020)
8.6.3.3 Forecast Trend (2021-2026)
8.6.4 Surgeries
8.6.4.1 Market Share
8.6.4.2 Historical Trend (2016-2020)
8.6.4.3 Forecast Trend (2021-2026)
8.6.5 Others
8.7 Global Anti-Fibrinolytic Drugs Market by End Use
8.7.1 Hospitals
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2016-2020)
8.7.1.3 Forecast Trend (2021-2026)
8.7.2 Ambulatory Surgery Centres
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2016-2020)
8.7.2.3 Forecast Trend (2021-2026)
8.7.3 Health Care Specialty Processes
8.7.3.1 Market Share
8.7.3.2 Historical Trend (2016-2020)
8.7.3.3 Forecast Trend (2021-2026)
8.7.4 Clinics
8.7.4.1 Market Share
8.7.4.2 Historical Trend (2016-2020)
8.7.4.3 Forecast Trend (2021-2026)
8.8 Global Anti-Fibrinolytic Drugs Market by Region
8.8.1 Market Share
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2016-2020)
9.1.2 Forecast Trend (2021-2026)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2016-2020)
9.2.2 Forecast Trend (2021-2026)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2016-2020)
9.3.2 Forecast Trend (2021-2026)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2016-2020)
9.4.2 Forecast Trend (2021-2026)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2016-2020)
9.5.2 Forecast Trend (2021-2026)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 EMR’s Key Indicators for Demand
10.4 EMR’s Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Pfizer Inc.
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Sanofi SA
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Akorn, Inc.
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Cadila Healthcare Ltd.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Takeda Pharmaceutical Company Limited
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Others
13 Industry Events and Developments
List of Figures and Tables
1. Global Anti-Fibrinolytic Drugs Market: Key Industry Highlights, 2016 and 2026
2. Global Anti-Fibrinolytic Drugs Historical Market: Breakup by Form (USD Billion), 2016-2020
3. Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by Form (USD Billion), 2021-2026
4. Global Anti-Fibrinolytic Drugs Historical Market: Breakup by Type (USD Billion), 2016-2020
5. Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by Type (USD Billion), 2021-2026
6. Global Anti-Fibrinolytic Drugs Historical Market: Breakup by Indication (USD Billion), 2016-2020
7. Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by Indication (USD Billion), 2021-2026
8. Global Anti-Fibrinolytic Drugs Historical Market: Breakup by End Use (USD Billion), 2016-2020
9. Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by End Use (USD Billion), 2021-2026
10. Global Anti-Fibrinolytic Drugs Historical Market: Breakup by Region (USD Billion), 2016-2020
11. Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by Region (USD Billion), 2021-2026
12. North America Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
13. North America Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
14. Europe Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
15. Europe Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
16. Asia Pacific Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
17. Asia Pacific Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
18. Latin America Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
19. Latin America Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
20. Middle East and Africa Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
21. Middle East and Africa Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
22. Global Anti-Fibrinolytic Drugs Market Structure
Key Questions Answered in the Report
The market is projected to grow at a CAGR of 5% between 2021 and 2026.
The major market drivers include the rising frequency of road accidents, increasing usage of the product in oral bleeding treatments, and the rising R&D investments in hemophilia products.
The key trends steering the market include the growing adoption of the drugs in the treatment of menorrhagia.
The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The major types of the drugs in the market are amicor, aminocaproic acid, aprotinin, lysteda, RiaSTAP, fibrinogen, tranexamic acid, and trasylol, among others.
Oral and injectable are the leading forms of the product in the industry.
The major indication segments within the market are gynaecology, hereditary angioedema, fibrinolytic response testing, and surgeries, among others.
The significant end use sectors within the market are hospitals, ambulatory centres, health care specialty processes, and clinics.
Pfizer Inc., Sanofi SA, Akorn, Inc, Cadila Healthcare Ltd., and Takeda Pharmaceutical Company Limited, among others, are the key industry players.
Analyst Review
The global anti-fibrinolytic drugs market is driven by the rising demand for the product in hemophilia treatments. Aided by the increasing investments in R&D, the market is expected to witness a healthy growth in the forecast period of 2021-2026, growing at a CAGR of 5%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. On the basis of form, the industry can be bifurcated into oral and injectable. Based on its types, the market can be segmented into amicor, aminocaproic acid, aprotinin, lysteda, riaSTAP, fibrinogen, tranexamic acid, and trasylol, among others. On the basis of indication, the market is divided into gynaecology, hereditary angioedema, fibrinolytic response testing, and surgeries, among others. By end use, the market is categorised into hospitals, ambulatory centres, health care specialty processes, and clinics. The major regional markets for the anti-fibrinolytic drugs are North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The key players in the above market include Pfizer Inc., Sanofi SA, Akorn, Inc, Cadila Healthcare Ltd., and Takeda Pharmaceutical Company, among others.
LimitedEMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The United States vaccine market attained a value of nearly USD 11.2 billion in 2020, driven by the rising use of mRNA technology in vaccine development. Aided by advancements in biotechnology and gen...
The global immunomodulators market attained an approximate value of USD 175 billion in 2020, driven by the rising prevalence of awareness among the masses regarding immunomodulators. Aided by the risi...
The global telmisartan market attained a value of about USD 3,574 million in 2020, driven by the rising cases of hypertension and cardiovascular diseases. Aided by the robustly growing pharmaceutical ...
The global doxorubicin market attained a value of about USD 1,075.90 million in 2020, driven by the rising cases of cancer worldwide. Aided by government investments in the pharmaceutical sector, the ...
The global radiopharmaceuticals market attained a value of about USD 4.3 billion, driven by rising applications in diagnostic and therapeutic segment. Aided by constant research and development and ri...
NEWSLETTER